BioMarin Pharmaceuticals financials
$59.87+0.69%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $989.7M | $766.2M | $874.6M | $776.1M | $825.4M | $745.1M | $747.3M | $745.7M | $712.0M | $648.8M | $646.2M | $581.3M |
| Gross profit | $786.9M | $571.2M | $598.9M | $636.0M | $675.3M | $593.6M | $611.2M | $557.3M | $581.6M | $523.7M | $508.3M | $453.3M |
| Gross margin | 79.5% | 74.6% | 68.5% | 82.0% | 81.8% | 79.7% | 81.8% | 74.7% | 81.7% | 80.7% | 78.7% | 78.0% |
| Operating income | $114.2M | $129.6M | -$44.6M | -$46.7M | $281.7M | $223.9M | $161.4M | $113.9M | $120.5M | $78.5M | $7.4M | $29.7M |
| Net income | $44.8M | $105.5M | -$46.6M | -$30.7M | $240.5M | $185.7M | $124.9M | $106.1M | $107.2M | $88.7M | $20.4M | $40.4M |
| Net margin | 4.5% | 13.8% | −5.3% | −4.0% | 29.1% | 24.9% | 16.7% | 14.2% | 15.1% | 13.7% | 3.2% | 6.9% |
| Diluted EPS | $0.23 | $0.54 | $-0.23 | $-0.16 | $1.23 | $0.95 | $0.66 | $0.55 | $0.55 | $0.46 | $0.11 | $0.21 |
| EBITDA | $211.8M | $146.1M | -$24.2M | -$28.2M | $300.3M | $246.0M | $185.0M | $132.9M | $146.9M | $105.8M | $7.4M | $55.4M |
| Operating cash flow | $168.1M | $220.7M | $99.6M | $368.7M | $185.3M | $174.4M | $185.6M | $221.5M | $118.8M | $47.0M | $27.5M | $135.6M |
| Free cash flow | $139.3M | $199.7M | $58.9M | $340.2M | $168.2M | $157.6M | $166.1M | $203.0M | $97.4M | $20.9M | -$1.4M | $113.9M |
| Diluted shares | 194.5M | 197.7M | 204.0M | 192.0M | 197.1M | 196.5M | 189.9M | 197.1M | 200.5M | 199.3M | 185.8M | 191.2M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $874.0M | $2.22B | $1.31B | $1.25B | $1.21B | $1.05B |
| Short-term investments | $0.00 | $0.00 | $248.9M | $227.7M | $218.3M | $223.5M |
| Total debt | $4.19B | $1.43B | $597.2M | $596.7M | $596.2M | $595.6M |
| Total assets | $11.72B | $8.59B | $7.59B | $7.61B | $7.46B | $7.15B |
| Total liabilities | $5.40B | $2.38B | $1.51B | $1.56B | $1.43B | $1.35B |
| Shareholders' equity | $6.32B | $6.21B | $6.09B | $6.06B | $6.03B | $5.79B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology